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Cyclic nucleotide phosphodiesterases (PDEs) are enzymes control-
ling cellular concentrations of the second messengers cAMP and
cGMP. The crystal structure of the catalytic domain of PDE9A2, a
member of a PDE family specifically hydrolyzing cGMP, has been
determined at 2.23-Å resolution. The PDE9A2 catalytic domain
closely resembles the cAMP-specific PDE4D2 but is significantly
different from the cGMP-specific PDE5A1, implying that each in-
dividual PDE family has its own characteristic substrate recognition
mechanism. The different conformations of the H and M loops
between PDE9A2 and PDE5A1 imply their less critical roles in
nucleotide recognition. The nonselective inhibitor 3-isobutyl-1-
methylxanthine (IBMX) binds to a similar subpocket in the active
sites of PDE4, PDE5, and PDE9 and has a common pattern of the
binding. However, significantly different orientations and interac-
tions of IBMXs are observed among the three PDE families and also
between two monomers of the PDE9A2 dimer. The kinetic prop-
erties of the PDE9A2 catalytic domain similar to those of full-length
PDE9A imply that the N-terminal regulatory domain does not
significantly alter the catalytic activity and the IBMX inhibition.
Twenty-one genes of human phosphodiesterase (PDE) arecategorized into 11 PDE families and share a conserved
catalytic domain with 300 aa (1–8). However, each PDE family
has varying substrate preferences and selective inhibitors. The
PDE4, PDE7, and PDE8 family members prefer to hydrolyze
cAMP, whereas PDE5, PDE6, and PDE9 are cGMP-specific.
PDE1, PDE2, PDE3, PDE10, and PDE11 show activities toward
both cAMP and cGMP (7). Selective inhibitors of PDEs have
been widely studied as therapeutics such as cardiotonics, vaso-
dilators, smooth-muscle relaxants, antidepressants, antithrom-
botics, antiasthmatics, and agents for improving cognitive func-
tions such as learning and memory (9–15). Many PDE inhibitors
have been in clinical trials or have already entered the market-
place. For example, the PDE3 selective inhibitor cilostazol
(Pletal) is a drug for the reduction of the symptoms of inter-
mittent claudication and the PDE5 inhibitors sildenafil (Viagra),
vardenafil (Levitra), and tadalafil (Cialis) are used for the
treatment of male erectile dysfunction.
Structural studies have shown that the catalytic domains of
PDE4 and PDE5 have similar folding, but the conformations of
H and M loops that are involved in binding of sildenafil and
rolipram are dramatically different (16–21). Thus, understand-
ing whether the conformations of PDE4 and PDE5 are two
representatives for the catalytic domains of other cAMP- and
cGMP-specific PDE families and whether the H and M loops
play a pivotal role in the substrate specificity and inhibitor
selectivity is essential for the illustration of the PDE functions.
Here, we report a crystal structure of the catalytic domain of
human PDE9A2 that is a cGMP-specific PDE with the highest
affinity for cGMP (Km  70 nM) and a low affinity for cAMP
(Km  230 M) (22, 23). The structural comparison surprisingly
reveals that the catalytic domain of PDE9A2 is closer to
PDE4D2 than PDE5A1.
Materials and Methods
Protein Expression and Purification. The catalytic domain of human
PDE9A2 (GenBank accession no. BC009047) was purchased
from American Type Culture Collection. A pair of oligonucle-
otide primers of gacgcgatcatatgacttaccccaagtacctg and tcaactc-
gagttacttcttctgtaactctttc were synthesized for amplification of the
PDE9A2 coding region of amino acids 181–506 by PCR. The
amplified PDE9A2 DNA and the expression vector pET15b
were digested separately by the restriction enzymes NdeI and
XhoI, purified from agarose gel, and then ligated by T4 DNA
ligase. The resultant plasmid pET-PDE9A2 was transformed
into Escherichia coli strain BL21 (Codonplus) for overexpres-
sion. The E. coli cell carrying pET-PDE9A2 was grown in LB
medium at 37°C to absorption A600  0.7, and then 0.1 mM
isopropyl -D-thiogalactopyranoside was added for further
growth at 15°C overnight. Recombinant PDE9A2 was purified
by the chromatographic columns of Ni-NTA affinity (Qiagen,
Valencia, CA), Q-Sepharose (Pharmacia), and Sephacryl S300
(Pharmacia). The Y424F mutant of the PDE9A2 catalytic
domain was subcloned by the site mutagenesis and purified by
using the same method as for the wild type. The PDE9A2
proteins had purity 95% as shown by SDSPAGE. A typical
batch of purification yielded 100 mg of PDE9A2 from a 2-liter
cell culture.
Enzymatic Properties. The enzymatic activities of the PDE9A2
domains were assayed by using 3H-cAMP and 3H-cGMP as
substrates. The PDE9A2 catalytic domain was incubated with
the reaction mixture of 50 mM TrisHCl (pH 7.8), 10 mM MgCl2,
and 3H-cAMP or 3H-cGMP (40,000 cpm per assay) at 24°C for
30 min. The reactions were terminated by addition of 0.2 M
ZnSO4 and 0.2 M Ba(OH)2. The reaction product 3H-AMP or
3H-GMP was precipitated by BaSO4, whereas unreacted 3H-
cAMP or 3H-cGMP remained in the supernatant. Radioactivity
in the supernatant was measured by liquid scintillation in a
Beckman–Coulter LS 6500 counter. The activity was measured
at eight concentrations of cAMP and cGMP, and each measure-
ment was repeated three times. Vmax and Km values were
calculated by linear plot of Lineweaver–Burk and nonlinear
regression of velocity versus substrate concentration. Eight
concentrations of 3-isobutyl-1-methylxanthine (IBMX) were
used in the determination of IC50.
Crystallization and Structure Determination. Crystals of PDE9A2–
IBMX were grown by vapor diffusion. The catalytic domain of
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10–15 mgml PDE9A2 (amino acids 181–506) in a storage buffer
of 50 mM NaCl, 20 mM TrisHCl (pH 7.5), 1 mM 2-mercapto-
ethanol, and 1 mM EDTA was mixed with 2 mM IBMX. The
PDE9A2–IBMX complex was crystallized by hanging drops at
4°C. The protein drops contain 3 l of PDE9A2–IBMX complex
and 1 l of well buffer of 0.1 M Hepes (pH 7.5), 2.2 M sodium
formate, and 5% xylitol. The well buffer plus 20% glycerol was
used as the cryosolvent for freezing the crystals in liquid
nitrogen. Diffraction data were collected on beamline X12C at
Brookhaven National Laboratory (Table 1) and processed by
program HKL (24). The PDE9A2–IBMX crystal has the space
group P41212 with cell dimensions of a  103.5 and c  269.7 Å.
The structure of PDE9A2–IBMX was solved by the molecular
replacement program AMORE (25), with the catalytic domain of
PDE4D2 as the initial model. The atomic model was rebuilt by
program O (26) against the electron density map improved by the
density modification package of CCP4. The structure was refined
by CNS (27) (Table 1).
Results and Discussion
Overall Structure. The catalytic domain of PDE9A2 (residues
181–506) consists of 16 helices (Fig. 1A). The superposition of
the PDE9A2 catalytic domain over PDE4D2 in PDE4D2–IBMX
(21) yielded an rms deviation of 1.5 Å for the C atoms of
residues 207–495 in PDE9A2 or residues 115–411 in PDE4D2,
showing that the two structures are very similar. The structure
variation is observed mainly in the N-terminal region that has a
totally different 3D arrangement. Residues 79–114 of PDE4D2
consist of two -helices and a 310-helix, but residues 181–206 of
PDE9A2 contain a single -helix. The residues after 207 of
PDE9A2 are superimposed very well over those of PDE4D2 and
possess similar elements of secondary structures, except for two
new 310 helices around residues 380 and 440 of PDE9A2 and an
extension of 10 residues in C-terminal helix H16 of PDE9A2
(Fig. 1 B and D). In addition, -helix H6 (residues 272–275) in
PDE9A2 corresponds to a 310-helix in PDE4D2.
On the other hand, the structure comparison of PDE9A2 with
PDE5A1 (21) shows significant differences in the conformations
of the two catalytic domains (Fig. 1C), as shown with an rms
deviation of 2.8 Å for the C atoms of 272 residues. Three
regions are not superimposable. The N-terminal residues 535–
567 of PDE5A1 contain two helices and have different 3D
arrangements from residues 181–206 of PDE9A2. The H loop
residues 301–316 in PDE9A2 or residues 661–676 in PDE5A1
have positional differences of 6–7 Å for the C atoms of two
short helices H8 and H9. The M loop residues 425–448 in
PDE9A2 are well ordered and contain a 310-helix; in contrast,
the majority of residues 787–812 in PDE5A1 are not traceable
and presumably exist in random conformation.
The crystallographic asymmetric unit of PDE9A2–IBMX
contains two molecules of the catalytic domains. The solvent
content is estimated to be 84% in the PDE9A2 crystal and is
unusually high in comparison with the solvent contents of 50%
and 47% in the crystals of PDE4D2 and PDE5A1. Despite high
solvent content, the surface loops involved in crystallographic
lattice contacts in PDE9A2 do not show significant conforma-
tion differences from those of PDE4D2. Two molecules of
PDE9A2 form a dimer in the crystal state (Fig. 2A). The
dimerization scheme of PDE9A2 is the same as that of PDE4D2,
and the key residues for the dimer interface are identical
between the two structures (Fig. 2 B and C). The interfacial
residues Tyr-315, Asn-316, Asp-317, Asn-323, and Arg-353 in
PDE9A2 form hydrogen bonds with one another and contribute
to the major force for formation of the dimer. These residues
correspond, respectively, to Tyr-223, Asn-224, Asp-225, Asn-231,
and Arg-261 in PDE4D2. However, the dimers of PDE9A2 do
not further associate into a tetramer, but PDE4D2 does. The
Sephacryl S300 gel filtration shows a peak position equivalent to
a molecular weight for a dimer of the PDE9A2 catalytic domain,
but further study is needed to identify the biologically active
oligomeric form of PDE9. Nevertheless, the identification of the
dimerization interface of PDE9 in the crystal state probably
rules out the potential role of the C-terminal residues in dimer-
ization.
Metal Binding. At the bottom of the active site, the two strongest
peaks 10 and 6 times the background in the omitted (2Fo 
Fc) map were assigned, respectively, as zinc and magnesium for
purposes of structural refinement. Although the metal assign-
ment is supported by the comparable B factors of the two metal
ions with protein residues in the refinement (Table 1), the nature
of the physiological ions is unknown. Although the first metal is
probably a zinc ion as identified in PDE4 (19), it remains
uncertain what is the identity of the second metal ion and
whether different PDE families have different catalytic metal
ions. Biochemical studies showed that manganese activated
PDE9A twice as much as magnesium or calcium did (23, 28), and
zinc was proposed to be the catalytic metal in the PDE5 family
(29). Our structural study showed that the two metal ions in
PDE9A2 occupy the same location as in the PDE4 and PDE5
structures (16, 19, 21). The first metal ion, presumably zinc,
forms six coordinations with His-256, His-292, Asp-293, Asp-
402, and two waters in an octahedral configuration. The second
metal ion also forms an octahedron with Asp-293 and five water
molecules.
Enzyme Activity. The catalytic domain of PDE9A2 has Km of
139  18 nM and Vmax of 1.53  0.24 molmin1mg1 for
cGMP, which are comparable with Km of 70–390 nM and Vmax
of 0.96–4.9 molmin1mg1 reported for the various isoforms
of full-length PDE9 (22, 23, 28). The IC50 value for nonselective
inhibitor 3-isobutyl-1-methylxanthine (IBMX) is 500 M for
the PDE9A2 catalytic domain, also consistent with IC50  230
M for the IBMX inhibition of the full-length PDE9A1 (23).
Thus, our data suggest that the N-terminal regulatory domain of
PDE9 may not have a significant impact on the enzymatic
activities nor potency of IBMX inhibition. The PDE9A2 cata-
Table 1. Statistics on diffraction data and structure refinement
Data collection PDE9A2–IBMX
Space group P41212
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lytic domain has Km of 181  17 M and Vmax of 0.08  0.015
molmin1mg1 for cAMP, 1,000 and 20 times worse than
cGMP, thus confirming that PDE9 is cGMP-specific.
The sequence alignment shows that PDE9 and PDE8 have a
tyrosine (Tyr-424 in PDE9A2) involved in interactions with
IBMX. Because PDE9 and PDE8 are insensitive to the inhibition
of IBMX (6) and this tyrosine corresponds to a phenylalanine in
the other PDEs that are inhibited by IBMX, it was interesting to
Fig. 1. Structures of the PDE–IBMX complexes. (A) Ribbon diagram of the catalytic domain of PDE9A2–IBMX. All the ribbon pictures in Figs. 1–3 are drawn by
RIBBONS (34). The -helices are cyan, the 310-helices are blue, the metal ions are pink, and IBMX is green. (B) Superposition of the N-terminal residues 79–119 and
loop 287–300 of PDE4D2 (golden) over PDE9A2 (light cyan). The remaining structures of PDE4D2 are very similar to PDE9A2 and are not shown. (C) Superposition
of three regions of PDE5A1 (green) over PDE9A2 (light cyan). These regions include the N-terminal residues 535–565 and H and M loops (residues 661–676 and
787–812). The remaining regions of PDE5A1 are similar to PDE9A2 and are not shown. (D) Sequence and secondary structures of the PDE catalytic domains.
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know whether the tyrosine to phenylalanine mutation sacrifices
the IBMX inhibition. We subcloned and purified the Y424F
mutant of the PDE9A2 catalytic domain. This mutant has a Km
of 135  21 nM and Vmax of 1.59  0.14 molmin1mg1 for
cGMP, and an IC50 of 450 M for IBMX. These enzymatic data
are comparable with those of the wild type of the PDE9A2
catalytic domain, thus suggesting that Tyr-424 does not play a
major role in IBMX binding. In the crystal of PDE9A2, the
hydroxide oxygen Tyr-424 is in a hydrogen bond distance (3.2 Å)
to N3 of xanthine of IBMX in molecule B, but interacts with the
isobutyl group in molecule A. Modeling of the Y424F mutation
shows that Phe-424 will be at a position perpendicular to the
xanthine ring and thus forms hydrophobic interactions with
IBMX. Because both the wild type and the Y424F mutant
interact with IBMX, the mutation may not have a significant
impact on the inhibitor binding. Thus, the nonsensitivity of
IBMX inhibition must be determined by other elements, which
are yet to be further explored.
Common and Distinct Interactions of IBMX in the PDE9A2 Dimer. The
electron density maps that were calculated from the PDE9A2
structure when IBMX was omitted reveal the specific binding of
IBMX at the active site with interactions similar to those in the
PDE4 and PDE5 structures (Fig. 3). The dimer of PDE9A2
contains two isolated sites for the binding of each IBMX. The
xanthine ring of IBMX stacks against Phe-456 of PDE9A2 on
one side and contacts residues Leu-420 and Tyr-424 on another
side. The N7 atom of xanthine forms a hydrogen bond with Ne2
of Gln-453. These interactions of IBMX within each monomer
are conserved in the PDE9A2 dimer. On the other hand
different orientations and interactions of two IBMXs in the
PDE9A2 dimer are observed. The xanthine rings of the two
respective IBMX molecules have a rotation difference of 50°
about an axis perpendicular to the xanthine ring, whereas the
stacking against Phe-456 is conserved in the dimer. As a result,
the atoms of IBMX have translational shifts of 0.6–4.7 Å, and
IBMX interacts uniquely with residues of Phe-251, His-252, and
Asn-405 in one monomer and Met-365 and Phe-441 in another.
In addition, isobutyl groups of the IBMX molecules have
different orientations in the two monomers and interact with
different residues: His-252 and Tyr-424 in one monomer and
Fig. 2. Ribbon presentation of dimers of PDE9A2 (A) and PDE4D2 (B) are shown, and the interface of the PDE9A2 dimer is shown in C.







Ile-403 and Phe-441 in the other. In contrast to the orientation
differences of IBMX in the dimer, two monomers of PDE9A2
protein have similar conformations, as shown by an rms devia-
tion of 0.36 Å from the superposition of C atoms of the entire
catalytic domain. In addition, the graphic display of the super-
position shows very similar conformations for the side chains of
the IBMX-binding residues.
The IBMX binding to the catalytic domain of PDE9A2 in the
crystal state is apparently inconsistent with the enzymatic data
that IBMX does not effectively inhibit the PDE9A2 catalytic
domain and full-length PDE9s (22, 23). A possible interpretation
may be that 2 mM IBMX, 10 times the protein concentration
of PDE9A2 in the crystallization drop, may be sufficient for high
occupancy of the binding pocket. A similar case has been
observed in the crystal structures of cyclophilin in complex with
the peptide substrates, where the peptides have dissociation
constants at the millimolar level (30, 31). Another explanation
may be that the tight binding of cGMP to PDE9A2 (Km  70 nM)
requires a higher concentration of IBMX for an effective
inhibition.
Variation of IBMX Binding in the Structures of PDE4, PDE5, and PDE9.
IBMX binds to the similar subpocket of the active sites of PDE4,
PDE5, and PDE9, which was proposed as a common site for
binding of nonselective inhibitors of PDEs (21). Two key factors
for binding of IBMX are absolutely conserved in the three
structures: stacking of xanthine against a phenylalanine (Phe-456
in PDE9A2) and a hydrogen bond between N7 of xanthine and
the glutamine side chain (Gln-453 in PDE9A2). The hydropho-
bic interactions of IBMX with Leu-420 and Tyr-424 of PDE9A2
are relatively conserved, as seen from the mutations of leucine
to valineisoleucine and tyrosine to phenylalanine across PDE
families.
On the other hand, the orientation of IBMX varies signifi-
cantly in the three structures. The xanthine ring of IBMX in
monomer A of the PDE9A2 dimer shows 15° rotation variation
and 1–1.5 Å translational shift from PDE4D2 and PDE5A1,
whereas IBMX in monomer B shows 2 Å of translation shift
from the structures of PDE4D2 and PDE5A1 (21). The expla-
nation of the orientation variation of IBMX binding is not clear.
A plausible interpretation may be that the much larger volume
of the active sites (450 Å3) than IBMX (180 Å3) would allow
variable orientations of IBMX under conservation of the hy-
drogen bond and stacking, because hydrophobic interaction is
nonspecific and one hydrogen bond is not sufficient to lock the
orientation of IBMX. Another possibility is that the subtly
different active sites of the PDE families require adjustment of
the IBMX orientation for the best fit.
The binding strength of IBMX in various PDEs may be
impacted by the conformation variation of the glutamine side
chain (Gln-369 in PDE4D2, Gln-817 in PDE5A1, and Gln-453
in PDE9A2) that forms the hydrogen bond with N7 of xanthine.
In PDE5A, the side-chain conformation of Gln-817 is fixed by
the hydrogen bond to Gln-775, which in turn hydrogen-bonds to
the carbonyl oxygen of the backbone Ala-767 and Ne1 of
Trp-853. In PDE4D2, the configuration of the Gln-369 side chain
is also fixed by its hydrogen bonding to Oh1 of Tyr-329, although
its side chain amide is 180° different from that of Gln-817 in
PDE5A1 (21). However, Gln-453 in PDE9A2, which has a
similar conformation to Gln-369 in PDE4D2, is not hydrogen-
bonded with Tyr-329-equivalent residue Ala-413 but a nearby
surrogate Glu-406. Although Glu-406 forms a hydrogen bond
with Ser-486, the pocket appears to have more room in PDE9A2
for fluctuation of the Gln-453 conformation. As a result, the
rigidity of the Gln-453 conformation is weakened, and its
capacity for binding of IBMX is reduced. In addition, the
carbonyl oxygen O6 of xanthine forms a hydrogen bond with Ne2
of Gln-817 in PDE5A or a water molecule bound to Asn-321 in
PDE4D2 but no obvious interactions with protein residues or
solvents in PDE9A2. Therefore, the absence of the interactions
may be a factor to account for the weak binding affinity of IBMX
for PDE9A2.
Implication for Substrate Specificity. Because IBMX and other
inhibitors do not significantly change the overall conformations
of PDE4 and PDE5 (16–21), we believe that the PDE9A2–
IBMX structure likely represents the native conformation of
PDE9A2 and thus is useful for discussions of substrate speci-
ficity, a central issue of enzymology. The classic lock–key and
induced-fit models both emphasize that a substrate fits the exact
conformation of the enzyme whether or not the active site
conformation is native or induced by substrate binding (32, 33).
Fig. 3. IBMX binding. (A) Stereoview of the electron density for IBMX bound to PDE9A2. The (2Fo  Fc) map was calculated from the structure omitting IBMX
and contoured at 2.0. (B) IBMX binding to the active site of PDE9A2. The xanthine group stacks against Phe-456 and forms a hydrogen bond with Gln-453. The
green balls-sticks represent IBMX in molecule A. The golden balls-sticks represent IBMX from molecule B, which is superimposed over molecule A. The dotted
line represents a hydrogen bond. The PDE9A2 residues that interact with IBMX in both monomers are shown in blue sticks, whereas the unique residues
interacting with IBMX in one monomer are drawn in green sticks (monomer A) and golden sticks (monomer B).
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On the basis of this conformation determination for substrate
specificity, one would predict that the active site of PDE9
resembles the cGMP-specific PDE5 more than it does the
cAMP-specific PDE4. However, the structural work in this
article shows an opposite result. The core catalytic domain of
PDE9A2 (residues 207–495) has identity of 86 and 85 residues
to PDE4D2 and PDE5A1, respectively. The structural superpo-
sition of the PDE9A2 core catalytic domain over those of PDE4
and PDE5 yields rms deviations of 1.5 and 2.8 Å, respectively, for
288 PDE4D2 and 272 PDE5A1 residues. This comparison shows
that the core catalytic domain of PDE9A2 has a conformation
closer to PDE4D2 than PDE5A1 and thus does not apparently
obey the prediction from the lock–key and induced-fit theories.
However, the superposition between the PDE9A2 and PDE5A1
catalytic domains, after exclusion of the H and M loops, yields
an rms deviation of 1.7 Å for 243 residues of PDE5A1. This
finding implies that the H and M loops do not play critical roles
in the specificity of nucleotide binding, although they are in-
volved in the binding of sildenafil and rolipram, respectively (18,
19). Thus, the substrate specificity in the PDE families must be
determined by subtle conformation differences and amino acid
variations of the remaining residues in the active sites, including
the environment around the absolutely conserved glutamine
(Gln-369 in PDE4D2, Gln-817 in PDE5A1, and Gln-453 in
PDE9A2). We postulate that each PDE family has a character-
istic recognition mechanism for substrate specificity, yet further
structural and biochemical studies are needed.
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